الأفراد المقيمين في المملكة المتحدة
| الأسم | سيرة شخصية |
|---|---|
| Mr مارك دونير | -- |
| Mr Daniel Podolsky | Mr Daniel Podolsky is Board Member at GlaxoSmithKline PLC. Mr. Daniel Podolsky, appointed on 1 July 2006. Daniel is President of the University of Texas Southwestern Medical Center and holds the Phillip O'Bryan Montgomery, Jr., M.D. Distinguished Presidential Chair in Academic Administration, and the Doris and Bryan Wildenthal Distinguished Chair in Medical Science. He is a member of the Institute of Medicine of the US National Academy of Sciences, a member of the board of the Southwestern Medical Foundation and is a director of Antibe Therapeutics, Inc.Daniel is President of the University of Texas Southwestern Medical Center in Dallas and holds the Philip O’Bryan Montgomery, Jr M.D. Distinguished Presidential Chair in Academic Administration, and the Doris and Bryan Wildenthal Distinguished Chair in Medical Science.Daniel is a member of the National Academy of Medicine at the US National Academy of Sciences, the Council of Teaching Hospitals of the Association of Academic Medical Centers, and sits on the Board of the Southwestern Medical Foundation. He is also a Director of Antibe Therapeutics, Inc., Agilent Technologies, Inc. and a member of the National Academies of Sciences Board on Army Science and Technology. |
| Mr Moncef Slaoui | Mr Moncef Slaoui is Board Member at GlaxoSmithKline PLC. Mr Slaoui owns 0.0009% in GlaxoSmithKline PLC since February 2015. Dr. Moncef Slaoui Appointed on 17 May 2006. Moncef joined GSK Biologicals in 1988 where he engineered the development of a robust vaccines pipeline and subsequently led Worldwide Business Development for pharmaceuticals before his appointment to lead R&D. Moncef was given overall responsibility for GSK's Oncology Business in 2010, and for GSK Vaccines in 2011. He has a PhD in Molecular Biology and Immunology from Université Libre de Bruxelles.Moncef joined GSK Vaccines in 1988 where he engineered the development of a robust vaccines pipeline. He then led Worldwide Business Development for pharmaceutical products before his appointment to lead R&D in 2006. He was given overall responsibility for GSK’s Oncology Business in 2010; for GSK Vaccines in 2011; and for all Global Franchises in 2012. Moncef has advised the US President’s Council of Advisors on Science and Technology and he was a member of the Board of the Agency for Science, Technology & Research (A*STAR) until January 2011. He has a PhD in Molecular Biology and Immunology from Université Libre de Bruxelles and has published more than 100 scientific papers and presentations. Prior to joining GSK, Moncef was Professor of Immunology at the University of Mons, Belgium. |
| Ms Rachel Lomax | Ms Rachel Lomax is Board Member at HSBC Holdings PLC. Ms Rachel Lomax joined the HSBC Board of Directors in 2008. She has experience in the public and private sectors, plus a deep knowledge of the operations of the UK government and financial system.Her previous appointments include Deputy Governor, Monetary Stability, at the Bank of England (BoE) and a member of the BoE’s Monetary Policy Committee; Permanent Secretary at the UK Government Departments for Transport and Work and Pensions and the Welsh Office; and Vice President and Chief of Staff to the President of the World Bank.She is the chairman of the International Regulatory Strategy Group and director of TheCityUK; director of Bruegel, a Brussels-based European think tank; non-executive director of Arcus European Infrastructure Fund GP LLP and Heathrow Airport Holdings Limited; member of the Council of Imperial College, London; trustee of the Ditchley Foundation; and President of the Institute of Fiscal Studies. She is also a non-executive director and chairman of the corporate responsibility committee of Serco Group plc.Rachel Lomax, Former Deputy Governor, Monetary Stability at the Bank of England from 2003 to 2008, where she was responsible for monetary assessment and money market operation. Prior to joining the Bank, Ms. Lomax served as Permanent Secretary for the Department of Transport and held the same position at the Department for Work and Pensions (1999 to 2002) and the Welsh Office (1996 to 1999). She served as Vice President and Chief of Staff to the President of the World Bank from 1995 to 1996, and was Head of the Economic and Domestic Secretariat at the Cabinet Office in 1994. Ms. Lomax is an independent, non-executive director of HSBC Holdings plc, The Scottish American Investment Company PLC and BAA Limited. |
| Ms لويز اوتيل فريسكو | -- |
| Ms جنفياف بيرغر | -- |
| جان مارك أوت | -- |
| Ms موراي كيسلر | -- |
| Ms نورا ميد برونيل | -- |
| Ms بيتسي هولدن | -- |
| Mr مارك كوتيفاني | -- |
| Ms آن كيرنز | -- |
| Mr جون دالي | -- |
| Mr Jonathan Evans | Mr Jonathan Evans is Board Member at HSBC Holdings PLC. Lord Evans of Weardale was appointed to the Board on 6 August 2013. He spent 33 years in the UK Security Service, six as Director General. Lord Evans’ experience includes counter-espionage, protection of classified information and the security of critical national infrastructure. Mr. Evans has been the global head of Growth Markets since January 2011, a Vice Chairman of Goldman Sachs since February 2008 and chairman of Goldman Sachs Asia since 2004. Prior to becoming a Vice Chairman, he had served as global co-head of Goldman Sachs’ securities business since 2003. Previously, he had been co-head of the Equities Division since 2001. Mr. Evans serves as a trustee of the Bendheim Center for Finance at Princeton University, serves as Chairman of the Board of Right to Play, USA, is a member of the Board of City Harvest and is a trustee of The Asia Society.In 2014 he became a peer, Lord Evans. He was appointed Knight Commander of the Order of the Bath in the 2013 New Year Honours List. He retired from the Security Service in April 2013. |
| مايكل ويليامز | -- |
| Mr بيتر جرواير | -- |
| Mr ان ستيفنز | -- |
| سيجردر سيجي اولفسون | -- |
| Mr جوزيف دبليو جوردور | -- |
| جاك ثيبثون | -- |
